​
​

CRISPR Therapeutics (CRSP) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

CRISPR Therapeutics Revenue Highlights

Latest Revenue (Y)

$370.00M

Latest Revenue (Q)

$602.00K

Main Segment (Y)

Collaboration Revenue

CRISPR Therapeutics Revenue by Period

CRISPR Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$370.00M84762.39%
2022-12-31$436.00K-99.95%
2021-12-31$913.08M168054.88%
2020-12-31$543.00K-99.81%
2019-12-31$289.59M9169.85%
2018-12-31$3.12M-92.38%
2017-12-31$41.00M693.90%
2016-12-31$5.16M1990.69%
2015-12-31$247.00K100.00%
2014-12-31--

CRISPR Therapeutics generated $370.00M in revenue during NA 2023, up 84762.39% compared to the previous quarter, and up 11843.79% compared to the same period a year ago.

CRISPR Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$602.00K16.44%
2024-06-30$517.00K2.58%
2024-03-31$504.00K-99.75%
2023-12-31$200.00M100.00%
2023-09-30--100.00%
2023-06-30$70.00M-30.00%
2023-03-31$100.00M1666566.67%
2022-12-31$6.00K-93.62%
2022-09-30$94.00K-40.51%
2022-06-30$158.00K-11.24%
2022-03-31$178.00K-98.56%
2021-12-31$12.35M3653.19%
2021-09-30$329.00K-99.96%
2021-06-30$900.20M445544.55%
2021-03-31$202.00K4.12%
2020-12-31$194.00K31.08%
2020-09-30$148.00K236.36%
2020-06-30$44.00K-71.97%
2020-03-31$157.00K-99.80%
2019-12-31$77.02M-63.66%
2019-09-30$211.93M66544.03%
2019-06-30$318.00K-3.05%
2019-03-31$328.00K185.22%
2018-12-31$115.00K-79.57%
2018-09-30$563.00K-48.25%
2018-06-30$1.09M-19.88%
2018-03-31$1.36M-95.80%
2017-12-31$32.33M1254.21%
2017-09-30$2.39M-33.36%
2017-06-30$3.58M32.52%
2017-03-31$2.70M15.32%
2016-12-31$2.34M51.32%
2016-09-30$1.55M94.84%
2016-06-30$795.00K67.02%
2016-03-31$476.00K92.71%
2015-12-31$247.00K100.00%
2015-09-30--

CRISPR Therapeutics generated $602.00K in revenue during Q3 2024, up 16.44% compared to the previous quarter, and up 0.86% compared to the same period a year ago.

CRISPR Therapeutics Revenue Breakdown

CRISPR Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Grant$1.21M$762.00K---
Collaboration Revenue$370.00M$436.00K---
Exclusive License--$900.00M--
Myotonic Dystrophy Type One License--$51.30M$51.30M$51.30M
Collaborative Arrangement Material Rights--$46.70M$46.70M$46.70M
Collaborative Arrangement Material Rights Fourth Exclusive License--$6.70M--
Duchenne Muscular Dystrophy License--$151.10M$151.10M$151.10M
Myotonic Dystrophy Type One R And D Services--$1.10M$1.10M$1.10M
Specified Target Option Material Right--$11.80M$11.80M$11.80M
Waiving Of Vertexs Material Right----$6.70M

CRISPR Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (99.68%), and Grant (0.32%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Jun 19Mar 19Dec 18
Grant$602.00K$517.00K$504.00K-----$762.00K$551.00K----------
Collaboration Revenue---$200.00M$70.00M$100.00M$6.00K$94.00K$158.00K$178.00K$12.35M---------
Specified Target Option Material Right-----------$11.80M$11.80M$11.80M$11.80M$11.80M$11.80M---
Collaborative Arrangement Material Rights-----------$46.70M$46.70M$46.70M$46.70M$46.70M$46.70M---
Duchenne Muscular Dystrophy License-----------$151.10M$151.10M$151.10M$151.10M$151.10M$151.10M---
Myotonic Dystrophy Type One License-----------$51.30M$51.30M$51.30M$51.30M$51.30M$51.30M---
Myotonic Dystrophy Type One R And D Services-----------$1.10M$1.10M$1.10M$1.10M$1.10M$1.10M---
License And Service-----------------$100.00K$100.00K$100.00K

CRISPR Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Grant (100.00%).

CRISPR Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
NVONovo Nordisk$232.26B$65.35B
REGNRegeneron Pharmaceuticals$13.12B$3.72B
SRPTSarepta Therapeutics$1.24B$362.93M
BEAMBeam Therapeutics$377.71M$14.27M
CRSPCRISPR Therapeutics$370.00M$602.00K
FATEFate Therapeutics$63.53M$6.77M
KRYSKrystal Biotech$50.70M$83.84M
NTLAIntellia Therapeutics$36.27M$9.11M
CRBUCaribou Biosciences$34.48M$3.46M
VERVVerve Therapeutics$11.76M$6.87M
EDITEditas Medicine--
CWBRCohBar--
AVROAVROBIO--
HEPAHepion Pharmaceuticals--

CRSP Revenue FAQ

What is CRISPR Therapeutics’s yearly revenue?

CRISPR Therapeutics's yearly revenue for 2023 was $370M, representing an increase of 84762.39% compared to 2022. The company's yearly revenue for 2022 was $436K, representing a decrease of -99.95% compared to 2021. CRSP's yearly revenue for 2021 was $913.08M, representing an increase of 168054.88% compared to 2020.

What is CRISPR Therapeutics’s quarterly revenue?

CRISPR Therapeutics's quarterly revenue for Q3 2024 was $602K, a 16.44% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $517K, a 2.58% increase from the previous quarter (Q1 2024), and a -99.26% decrease year-over-year (Q2 2023). CRSP's quarterly revenue for Q1 2024 was $504K, a -99.75% decrease from the previous quarter (Q4 2023), and a -99.50% decrease year-over-year (Q1 2023).

What is CRISPR Therapeutics’s revenue growth rate?

CRISPR Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -59.48%, and for the last 5 years (2019-2023) was 27.77%.

What are CRISPR Therapeutics’s revenue streams?

CRISPR Therapeutics's revenue streams in c 23 are Grant, and Collaboration Revenue. Grant generated $1.21M in revenue, accounting 0.32% of the company's total revenue, up 58.27% year-over-year. Collaboration Revenue generated $370M in revenue, accounting 99.68% of the company's total revenue, up 84762.39% year-over-year.

What is CRISPR Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of CRISPR Therapeutics was Collaboration Revenue. This segment made a revenue of $370M, representing 99.68% of the company's total revenue.